Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. announced the release of its financial results for Q4 and full year 2023, focusing on mRNA medicines, infectious disease vaccines, and rare diseases. The earnings conference call will be held on March 7, 2024, at 4:30 p.m. ET.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2023 after the market close on Thursday, March 7 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 7, 2024.

Arcturus Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call

• Thursday, March 7, 2024 @ 4:30 p.m. ET
• Domestic: 1-877-407-0784
• International: 1-201-689-8560
• Conference ID: 13744044
• Webcast: Link

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR^® lipid-mediated delivery, (ii) STARR^® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220483960/en/

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

VP, Head of IR/PR/Marketing

(858) 900-2682

IR@arcturusrx.com

Source: Arcturus Therapeutics Holdings Inc.

When will Arcturus Therapeutics release its financial results for Q4 and full year 2023?

Arcturus Therapeutics will release its financial results for Q4 and full year 2023 after the market close on Thursday, March 7, 2024.

What is the focus of Arcturus Therapeutics' development efforts?

Arcturus Therapeutics focuses on the development of mRNA medicines, infectious disease vaccines, and opportunities within liver and respiratory rare diseases.

When is the earnings conference call scheduled for Arcturus Therapeutics?

The earnings conference call for Arcturus Therapeutics is scheduled for Thursday, March 7, 2024, at 4:30 p.m. Eastern Time.